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a twofold increase in glomerular TGF-b RII protein expression,Effects of diabetes and hypertension on glomerular trans-
but did not reproduce the effect of diabetes mellitus on TGF-bforming growth factor-b receptor expression.
RI expression. In contrast to the findings in SHRs, neitherBackground. Several studies have suggested that trans-
hyperglycemia (blood glucose level, 15.5 6 2.1 mmol/L), unin-forming growth factor-b1 (TGF-b1) is an important determi-
ephrectomy, nor hyperglycemia (blood glucose level, 16.8 6nant of diabetic glomerular injury. TGF-b1 forms a hetero-
3.0 mmol/L) and uninephrectomy altered TGF-b receptor ex-meric complex with two cellular receptor subtypes, designated
pression in the glomeruli of normotensive WKY rats.TGF-b RII and TGF-b RI, but the effects of diabetes mellitus
Conclusion. These studies support the hypothesis that he-on glomerular TGF-b receptor expression have not been com-
modynamic factors and metabolic factors influence glomerularpletely elucidated. We first compared the effect of experimental
TGF-b receptor in vivo in the SHRs.type I diabetes mellitus and uninephrectomy on glomerular
TGF-b receptor expression in spontaneously hypertensive rats
(SHRs), and then sought to determine whether changes in
TGF-b receptor expression were strain specific by studying Diabetic nephropathy is characterized by a rapidnormotensive Wistar-Kyoto (WKY) rats.
phase of renal growth following the onset of hyperglyce-Methods. Five groups of male SHRs were studied. The first
mia so that both whole kidney weight and glomerulargroup received streptozotocin (60 mg/kg IV) and was studied
after one week. The second group received streptozotocin and volume increase [1–5]. Later, diabetic nephropathy is
was studied after two weeks. The third group received strepto- characterized by progressive mesangial expansion and a
zotocin (60 mg/kg IV) but received insulin to maintain eugly- decrease in glomerular filtration rate [6–8]. The mecha-cemia. The fourth group of age-matched SHRs served as the
nisms responsible for diabetic glomerular hypertrophycontrol group, while a fifth group of SHRs underwent unine-
and injury have not been completely elucidated [8, 9],phrectomy. Four groups of male WKY rats were also studied.
The first group of WKY rats served as the age-matched control but a number of studies suggest that transforming growth
group. The second group of WKY rats received streptozotocin, factor-b1 (TGF-b1) plays a central role in these pro-
while a third group of WKY rats underwent uninephrectomy. cesses [10–14]. TGF-b1 exerts biological effects by inter-The fourth group underwent uninephrectomy and received
acting with specific cell-surface receptors, including astreptozotocin. At each time point, glomeruli were isolated for
type I receptor (TGF-b RI, 53 kD) and a type II receptorprotein extraction, and the protein was subjected to Western
blot analysis of TGF-b RII and TGF-b RI expression. (TGF-b RII, 75 kD) [15–19]. TGF-b RI [20, 21] and
Results. Basal expression of both TGF-b receptors per mi- TGF-b RII [22] form a heteromeric signaling complex
crogram of glomerular protein was similar in normotensive with the ligand TGF-b1, and each receptor is necessaryWKY rats and hypertensive SHRs. Hyperglycemia (blood glu-
for TGF-b1 cell signaling [23–26]. Although the effectcose level, 17.8 6 2.9 mmol/L) led to an early twofold increase
of experimental type I diabetes mellitus on TGF-b1 ex-in TGF-b RII protein expression and a fourfold increase in
TGF-b RI protein expression in the glomeruli of hypertensive pression has been studied extensively [27–30], the effect
diabetic SHRs compared with euglycemic SHRs (blood glucose of diabetes mellitus on TGF-b receptor expression in
level, 5.8 6 0.8 mmol/L), which was sustained after two weeks. the glomerulus has not been clearly defined.Insulin treatment (blood glucose level, 5.2 6 0.9 mmol/L) nor-
Accordingly, we studied TGF-b receptor expressionmalized both TGF-b RII and TGF-b RI expression in the
in glomeruli of rats with early streptozotocin-inducedglomeruli of SHRs that received streptozotocin. Glomerular
capillary hypertension in the uninephrectomized SHRs led to diabetes mellitus. We chose to study the spontaneously
hypertensive rat (SHR) because streptozotocin-induced
diabetes is accompanied by an approximately 10 mm HgKey words: glomerular injury, hyperglycemia, streptozotocin, blood
pressure, uninephrectomy, capillary hypertension. increase in glomerular capillary hydrostatic pressure in
the SHR [31–34], and micropuncture studies of diabeticReceived for publication November 20, 1998
rats suggest that increased glomerular capillary pressureand in revised form April 19, 2000
Accepted for publication April 25, 2000 is an important determinant of diabetic glomerular injury
[35, 36]. We also studied the SHR because, unlike normo-Ó 2000 by the International Society of Nephrology
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tensive rats strains, uninephrectomy leads to a 10 mm Hg uli were isolated from both groups two weeks after sur-
increase in glomerular capillary pressure in the SHR gery (N 5 6), and micropuncture studies were performed
[31–33]. Studies of glomeruli from uninephrectomized in separate animals (N 5 4). A group of WKY rats (N 5
SHRs therefore enabled us to determine whether capil- 6) also underwent uninephrectomy and was studied after
lary hypertension influenced glomerular TGF-b receptor one week. Intact WKY rats served as the control group
expression in the absence of hyperglycemia. Finally, we (N 5 6).
sought to determine whether diabetes-induced changes
Glomerular isolationin glomerular TGF-b receptor expression were strain
specific by studying streptozotocin-induced diabetes mel- Kidneys were rapidly removed. The perirenal fat and
litus in normotensive Wistar-Kyoto (WKY) rats. capsule were stripped off, and the cortex was separated
from the medulla. Cortical pieces were placed into ice-
cold phosphate-buffered saline (PBS) buffer (pH 7.4)METHODS
and cut into 2 mm3 pieces, and glomeruli were isolated
Animal model by the technique of differential sieving as previously
Twelve- to 14-week-old male SHRs (N 5 48) and described. Cortical tissue from three rats was pooled and
normotensive WKY (N 5 26) rats were used in all of the then passed through a 250 mm sieve and resuspended in
experimental protocols (Harlan Bioproducts for Science, ice-cold PBS before being centrifuged at 1000 r.p.m. for
Inc., Indianapolis, IN, USA). Awake systolic blood pres- five minutes at 48C. The pellet was resuspended and then
sure (SBP) was measured by the tail-cuff method, and drawn up and discharged three times through a 21-gauge
rats were randomly assigned to the experimental groups. needle. This material was then passed through a 106 mm
The first three groups of SHR received streptozotocin sieve and then a 75 mm sieve. Glomeruli were collected
(60 mg/kg body weight) via a single tail vein injection. from the 75 mm sieve and were resuspended in ice-cold
Blood samples from tail were obtained 24 hours after PBS. All solutions were diethyl pyrocarbonate treated.
the administration of streptozotocin for determination of The purity of the final suspension was determined by
blood glucose levels with an Ames Accutest Glucometer. light microscopic examination. The requirement was for
After the onset of hyperglycemia (defined as blood glu- fewer than five tubular fragments per 100 glomeruli.
cose levels greater than 15 mmol/L), blood glucose levels
were measured daily, and rats were excluded if their Western blot analysis of glomerular proteins
blood glucose levels failed to remain above 15 mmol/L.
After glomerular isolation by differential sieving, glo-
Two groups of diabetic SHR remained untreated (N 5
meruli were homogenized in a RIPA buffer containing6 in each group), while a third group received ultralente
1 3 PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1%insulin to maintain normoglycemia (heat-treated ul-
sodium dodecyl sulfate (SDS), 10 0.1 mg/mL phenyl-tralente insulin, N 5 6; Novo Industri A/S, Copenhagen,
methylsulfonyl fluoride (PMSF), 30 mg/mL aprotinin, 1Denmark). A final group of SHRs underwent unin-
mmol/L sodium orthovanadate as previously described.ephrectomy (N 5 6). Diabetic SHRs were studied after
Homogenates were centrifuged at 3000 r.p.m. for 10 min-one week (N 5 6) and after two weeks (N 5 6) of
utes. The supernatant was separated, and the protein con-hyperglycemia. The uninephrectomized SHRs were
centration was measured with a Bio-Rad Protein Assaystudied two weeks after surgery. Ultralente insulin-
Kit. For Western blot analysis, 40 mg of protein weretreated SHRs were studied one week after the adminis-
separated using 10% sodium dodecyl sulfate-polyacryl-tration of streptozotocin (N 5 6). At each time point,
amide gel electrophoresis (SDS-PAGE) under reducingnormal SHRs served as the control group (N 5 24). A
conditions and then transferred to a nitrocellulose mem-first group of WKY rats (N 5 6) received streptozotocin
brane (PROTRAN; Schleicher & Schuell, Dassal, Ger-(60 mg/kg body weight) via a single tail vein injection
many). The nitrocellulose membrane was blocked withand were studied after one week. A second group of
TTBS solution containing 5% nonfat powdered milk andWKY rats underwent a uninephrectomy and were stud-
incubated for three hours with either rabbit polyclonalied after one week. A third group of WKY rats (N 5
TGF-b RI (ALK5, catalog #SC398) or TGF-b RII anti-4) received streptozotocin, underwent a uninephrec-
sera (catalog #SC400; Santa Cruz Biochemical, Santatomy, and were then studied after one week. Normal
Cruz, CA, USA). Membranes were then incubated withWKY rats served as the control group (N 5 10). All of
a peroxidase-conjugated antirabbit secondary antibody,the animals were allowed free access to standard food
and the Western blot was developed with an ECL West-and water.
ern Blotting Analysis System (KPL, Gaithersburg, MD,After awake SBP measurement, 12- to 14-week-old
USA) using X-OMAT autoradiography film (Eastmanhypertensive SHRs (N 5 10) were randomly assigned to
Kodak, Rochester, NY, USA). Autoradiograms wereundergo right nephrectomy or sham nephrectomy under
Brietal anesthesia (50 mg/kg intraperitoneally). Glomer- quantitated by scanning densitometry.
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Table 1. Spontaneously hypertensive rate (SHR) experiment data decline in body weight so that one week after the onset
of hyperglycemia, diabetic SHRs weighed 221 6 16 g,BW LKW
KW/BW BG
while normoglycemic control rats weighed 313 6 8 g.N g % mmol/L
Two weeks after the onset of hyperglycemia, the diabetic
Control 24 31368 1.0960.08 0.3560.01 5.560.8
SHRs weighed 223 6 20 g. Despite the decline in bodyDM (1 week) 6 221616a 1.0260.09 0.4660.04a 17.862.9a
DM (2 weeks) 6 223620a 1.0660.07 0.4760.03a 18.161.8a weight, kidney weights were maintained in diabetic
DM (Rx) 6 33069a 1.0360.05 0.3260.02 5.260.9 SHRs so that there was a significant increase in the ratio
Unx 6 358611a 1.8160.10a 0.5060.05a —
of wet kidney weight to body weight in the diabetic
Abbreviations are: DM, diabetes mellitus; Rx, insulin treatment; Unx, uni-
SHRs. Blood glucose levels averaged 17.8 6 2.9 andnephrectomy; N, number of rats; BW, body weight; KW, body weight; BW/KW,
% body weight/kidney weight; BG, blood glucose. Values are mean 6 standard 18.1 6 1.8 mmol/L in the diabetic SHRs after one and
error.
two weeks, respectively. Ultralente insulin treatment toa P , 0.05 vs. Control
maintain euglycemia in SHRs that received streptozo-
tocin normalized body weight and the wet kidney weight
to body weight ratio. The increase in the ratio of wet
Micropuncture studies kidney weight to body weight ratio two weeks after unin-
ephrectomy was similar to that observed in the diabeticMicropuncture studies were performed in sham-oper-
SHRs (0.50 6 0.05% in the uninephrectomized SHRsated SHRs and untreated uninephrectomized SHR-Unix
vs. 0.47 6 0.03% in the diabetic SHRs).(N 5 4). Rats were anesthetized with Inactin (100 mg/kg
Transforming growth factor-b receptor expression wasintraperitoneally) and were placed on a temperature-
assessed by Western blot analysis in glomeruli from eachregulated micropuncture table. A PE-50 tubing was in-
group of SHRs and was compared with age-matchedserted into the left femoral artery and used to monitor
normal SHRs. As expected, TGF-b RI protein was de-mean arterial pressure and to obtain arterial blood
tected as a single band with a molecular weight of ap-samples. The mean arterial pressure was monitored con-
proximately 55 kD, while TGF-b RII protein was de-tinuously with an electronic transducer connected to a
tected as a single band with a molecular weight ofdual-channel direct writing recorder. After tracheos-
approximately 70 kD. TGF-b RI protein expression in-tomy, PE-50 catheters were introduced into the right
creased fourfold in the glomeruli of diabetic SHRs oneand left internal jugular veins for infusion of rat plasma
week after the onset of hyperglycemia, compared withand saline. A PE-10 catheter was inserted into the left
control SHRs, and remained elevated approximately 2.8-ureter. After insertion of the jugular catheters, 1%
fold in glomeruli two weeks after the onset of hyperglyce-body weight plasma was infused over 35 to 45 minutes,
mia. Representative immunoblots and the mean valuesfollowed by a plasma infusion of approximately 0.50
for densitometry are shown in Figure 1 A and B. Treat-mL/hour [50]. Saline was infused at a rate of 2.0 mL/hour.
ment with insulin to normalize blood glucose levels alsoA continuous-recording servo-null micropipette trans-
normalized TGF-b RI expression (Fig. 1C). TGF-b RIIducer system (Model V; Instrumentation for Physiology
protein expression increased twofold in the glomeruli ofand Medicine, San Diego, CA, USA) was used to obtain
diabetic SHRs, one week after the onset of hyperglyce-time-averaged hydraulic pressures in surface proximal
mia, compared with control SHRs, and remained ele-tubules after blockade with an oil droplet in free-flowing
vated approximately 1.6-fold in glomeruli after twoproximal tubules. Hydraulic output from the servo-null
weeks. Representative immunoblots and the mean val-was transmitted to the second channel of the direct writ-
ues for densitometry are shown in Figure 2 A and B.ing recorder by means of a pressure transducer.
Treatment with insulin to normalize blood glucose levels
Statistical analysis also normalized TGF-b RII expression (Fig. 2C).
Micropuncture studies were performed two weeksStatistical analysis of differences between values of
after surgery to confirm that uninephrectomy led to anindividual parameters was evaluated by the t-test be-
increase in glomerular capillary pressure compared withtween normal rats and rats in each of the experimental
sham-operated intact SHRs. The mean value for glomer-groups. Significance was defined as P , 0.05. Values are
ular capillary pressure in intact SHR was 54 6 1 mm Hgexpressed as mean 6 SD.
compared with 62 6 1 mm Hg in the uninephrectomized
SHRs (P , 0.05). Mean values for transcapillary hydrau-
RESULTS lic pressure gradient were also different between the two
Prior to group assignment, SHRs weighed an average groups, averaging 42 6 1 mm Hg in the control group
of 270 6 7 g, and the awake SBP values averaged 205 6 and 53 6 1 mm Hg in the uninephrectomized SHR (P ,
10 mm Hg (N 5 48). Table 1 shows the whole animal 0.05), because values for proximal tubular hydraulic
data for each of the experiments involving the SHRs. pressure were similar. TGF-b RI protein expression did
not increase in the glomeruli of SHRs two weeks afterThe administration of streptozotocin was followed by a
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Fig. 1. Western blot analysis and densitome-
try measures of transforming growth factor-b
receptor I (TGF-b RI) expression in sponta-
neously hypertensive rat (SHR) glomeruli
after one week of hyperglycemia (A), after
two weeks of hyperglycemia (B), and after
insulin treatment to normalize blood glucose
levels (C; N 5 6, *P , 0.05).
Fig. 2. Western blot analysis and densitome-
try measures of TGF-b RII expression in SHR
glomeruli after one week of hyperglycemia
(A), after two weeks of hyperglycemia (B),
and after one week of insulin treatment to
normalize blood glucose levels (C; N 5 6, *P ,
0.05).
Fig. 3. Western blot analysis and densitome-
try measures of TGF-b RI expression (A) and
TGF-b RII expression (B) in glomeruli from
normal SHR (control) and uninephrectom-
ized SHR (Unx, N 5 6, *P , 0.05) after two
weeks.
uninephrectomy when glomerular capillary hypertension
was established, compared to control SHRs. Representa-
tive immunoblots and the mean values for densitometry
are represented in Figure 3A. In contrast, TGF-b RII
protein expression increased approximately 1.9 fold (Fig.
Table 2. Wistar Kyoto (WKY) rat experimental data3B) in the glomeruli of uninephrectomized SHRs with
capillary hypertension. BW LKW
KW/BW BGTo determine whether the previously mentioned
N g % mmol/L
changes were strain specific, experiments were per-
Control 10 23065 0.9460.04 0.4060.01 5.360.8formed in normotensive 10- to 12-week-old WKY rats.
DM 6 206614a 1.1060.05a 0.5360.04a 15.562.1a
Prior to group assignment, the WKY rats weighed an Unx 6 23766 1.1560.08a 0.4960.02a —
DM (Unx) 4 190610a 1.1760.07a 0.6160.06a 16.863.0aaverage of 232 6 14 g, and awake SBP levels averaged
Abbreviations are: DM, diabetes mellitus; Unx, uninephrectomy; N, number140 6 10 mm Hg (N 5 26). Table 2 shows whole animal
of rats; BW, body weight; KW, body weight; BW/KW, % body weight/kidneydata for each of the experiments involving the WKY weight; BG, blood glucose. Values are mean 6 standard error.
a P , 0.05 vs. Controlrats.
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Fig. 4. Western blot analysis and densitome-
try measures of TGF-b RI expression (A) and
TGF-b RII expression (B) in glomeruli from
normal SHRs and normal WKY rats (N 5 6).
Fig. 5. Western blot analysis and densitome-
try measures of TGF-b RI expression (A) and
TGF-b RII expression (B) in glomeruli from
control WKY rats and diabetic WKY rats
(N 5 6) after one week.
The administration of streptozotocin was followed by capillary hypertension in the normotensive WKY rat,
a decline in body weight so that one week after the onset and the maneuver did not affect glomerular TGF-b RI
of hyperglycemia, diabetic WKY rats weighed 206 6 and TGF-b RII expression (Fig. 6). Finally, we examined
14 g, while normoglycemic control rats weighed 230 6 the effect of uninephrectomy and diabetes mellitus on
5 g (P , 0.05). The kidney weight increased in the dia- glomerular TGF-b expression, and like each individual
betic WKY rat so that there was a significant increase maneuver, the combination did not influence glomerular
in the ratio of wet kidney weight to body weight (0.40 6 expression of the receptors (Fig. 7).
0.01% in the control WKY rat vs. 0.53 6 0.04% in the
diabetic WKY rat, P , 0.05). Blood glucose levels aver-
DISCUSSIONaged 15.5 6 2.1 mmol/L, similar to the values obtained
Although the pathogenesis of diabetic nephropathy hasin the diabetic SHRs. Uninephrectomy led to an increase
not been fully elucidated, a number of studies suggest thatin kidney weight and an increase in the ratio of wet
the growth factor/cytokine TGF-b1 plays an importantkidney weight to body weight (0.49 6 0.02% in the unin-
role [27–30]. In vitro, TGF-b1 stimulates cell hypertrophyephrectomized WKY rat vs. 0.40 6 0.01% in the control
and extracellular matrix protein synthesis by mesangialWKY rat, P , 0.05). The combination of diabetes and
cells and proximal tubule epithelial cells [10–12, 37–41],uninephrectomy also led to an increase in kidney weight.
and high glucose concentrations increase TGF-b1 mRNADespite similar levels of basal expression of TGF-b
levels in mesangial cells [42–44] and proximal tubuleRI and TGF-b RII in the glomeruli of intact, normal
cells [45]. In accord with these observations, Border andSHRs and WKY rats (Fig. 4), neither TGF-b RI protein
colleagues have shown that there are sustained increasesexpression nor TGF-b RII protein expression increased
in TGF-b1 mRNA levels and TGF-b1 immunostainingin the glomeruli of diabetic WKY rats one week after
in diabetic glomeruli [27–29], and enhanced TGF-b1 ex-the onset of hyperglycemia, compared with glomeruli
pression correlates with increased extracellular matrixfrom control WKY rats. Representative immunoblots of
protein accumulation in the mesangium [27–29]. IncreasedTGF-b RI, TGF-b RII, and the mean values for densi-
TGF-b1 expression is associated with increased TGF-b1tometry are shown in Figure 5 A and B, respectively.
Uninephrectomy was not accompanied by glomerular bioactivity in experimental diabetes mellitus, because
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Fig. 6. Western blot analysis and densitome-
try measures of TGF-b RI expression (A) and
TGF-b RII expression (B) in glomeruli from
control WKY rats and uninephrectomized
WKY rats (N 5 6) after one week.
Fig. 7. Western blot analysis and densitome-
try measures of TGF-b RI expression (A) and
TGF-b RII expression (B) in glomeruli from
control WKY rats and uninephrectomized di-
abetic WKY rats (N 5 4) after one week.
treatment with TGF-b1 neutralizing antibodies lowers abolished if the serine-threonine kinase activity of either
of the type I or type II receptor is ablated, and thus, bothextracellular matrix protein mRNA levels in the kidneys
of streptozotocin-induced diabetic mice and attenuates receptor subtypes are essential for TGF-b1 signaling to
occur [23–26].hypertrophy [30].
Transforming growth factor-b1 leads to cell hypertro- There is limited information on the regulation of ex-
pression of glomerular TGF-b receptors [41], and it isphy and extracellular matrix protein synthesis by binding
to specific receptors on the cell surface [18, 19], and possible that in vivo, diabetes-induced changes in TGF-b
receptor expression may contribute to the cellular re-radioligand studies have identified high-affinity receptors
for TGF-b1 in mesangial cells and isolated glomeruli sponse to the diabetic milieu. Therefore, the first goal
of the current study was to determine the effect of experi-[15, 16]. Although five TGF-b receptor subtypes have
been identified, the signaling pathways have been best mental type I diabetes mellitus on TGF-b receptor ex-
pression in the glomerulus. We performed studies incharacterized for the type II receptor and type I receptor
[17–19]. The type II receptor is a 70 kD transmembrane SHRs because micropuncture studies of diabetic rats
suggest that increased glomerular capillary pressure isprotein [22] that functions as a serine-threonine kinase.
The type II receptor, which is constitutively phosphory- an important determinant of diabetic glomerular injury,
independent of the level of glycemic control [35, 36].lated, binds TGF-b1 and then associates with and phos-
phorylates the type I receptor, a 55 kD transmembrane Banks and coworkers have reported that streptozotocin-
induced hyperglycemia in the SHR, like other studies ofprotein [46–49]. A number of type I receptors have been
cloned, some of which share homology with that activin experimental diabetes mellitus [35, 36], is accompanied
by an approximately 10 mm Hg increase in glomerularreceptors [20, 21, 50]. A signaling murine type I receptor
(designated Tsk7 l) was first cloned and characterized capillary hydrostatic pressure [34]. The other important
advantage of the SHR is that uninephrectomy leads toby Ebner et al [21], but was subsequently found to be
homologous to an activin type I receptor. More recently, a similar increase in glomerular capillary hydrostatic
pressure [31]. Therefore, studies of TGF-b receptorexperimental work suggests that another type I receptor,
ALK5 (also designated R4), is the important type I re- expression in isolated glomeruli from streptozotocin-
induced diabetic SHRs and uninephrectomized SHRsceptor involved in the transmembrane signaling of
TGF-b1 [50]. The intracellular effects of TGF-b1 can be were performed in order to separate effects of glomeru-
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lar capillary hypertension from effects of hyperglycemia RII expression accompany excisional wound repair [54],
and it is possible that increased expression of RII mightand insulin deficiency.
Our first major observation was that hyperglycemia increase in vivo ligand binding. In support of this hypoth-
esis, Riser et al have recently reported that both highled to a sustained increase in expression of both the RI
and RII TGF-b receptors in glomeruli of diabetic SHRs glucose and mechanical strain increase TGF-b receptor
expression in cultured mesangial cells and that increasedcompared with age-matched normoglycemic SHRs dur-
ing the early phase of renal hypertrophy when the kidney expression is accompanied by increased ligand binding
[55]. In addition to effects on ligand binding, increasedweight/body weight ratio increases. Treatment with insu-
lin to normalize blood glucose levels from rising after RI receptor expression might also influence TGF-b1 bio-
activity, because McCaffery et al have reported thatadministration of streptozotocin prevented the increase
in kidney weight/body weight ratio and also normalized TGF-b1–induced collagen synthesis is enhanced in vas-
cular smooth muscle cells from atherosclerotic lesionsglomerular TGF-b RII and RI receptor. Thus, changes
in TGF-b receptor expression in glomeruli of SHR fol- that exhibit a high ratio of RI to R II TGF-b receptor
expression compared with normal cells [56]. Althoughlowing streptozotocin-induced type I diabetes mellitus
were not due to streptozotocin toxicity, but rather were similar studies have not been performed in mesangial
cells, increases in the RI to RII ratio in the glomerulusdependent on the hyperglycemic diabetic state.
Streptozotocin-induced diabetes mellitus in the SHRs might serve to enhance the fibrotic response to TGF-b1
and contribute to diabetic glomerular injury.is associated with both systemic and intraglomerular hy-
pertension [34]; therefore, the second goal of the current The final goal of the current report was to determine
whether the effects of diabetes mellitus on TGF-b recep-study was to determine whether systemic and intraglo-
merular hypertension increased glomerular TGF-b re- tor expression were strain specific because in vitro stud-
ies have identified differences in the regulation of TGF-bceptor expression in the absence of diabetes mellitus.
Since uninephrectomy in hypertensive SHRs leads to receptor expression by angiotensin II in vascular smooth
muscle cells derived from SHRs and WKY rats [57]. Toglomerular capillary hypertension without diabetes mel-
litus and uncomplicated by remnant kidney tissue [31], test this hypothesis, we chose to study TGF-b receptor
expression in the glomeruli of control WKY rats, diabeticwe studied TGF-b receptor expression in the glomeruli
of uninephrectomized SHRs to test the hypothesis that WKY rats, and uninephrectomized WKY rats. We first
compared TGF-b receptor expression in the glomerulichanges in TGF-b receptor expression were secondary
to hemodynamic factors rather than metabolic factors. of normal SHRs and normal WKY rats. TGF-b receptor
protein expression was similar in the two strains. How-Our second major observation was that uninephrectomy
did not reproduce the effect of diabetes mellitus on ever, in contrast to the SHRs, neither streptozotocin-
induced diabetes mellitus nor uninephrectomy (or theTGF-b receptor expression in the SHRs. Systemic and
glomerular capillary hypertension in the uninephrectom- two maneuvers combined) influenced glomerular TGF-b
receptor expression in normotensive WKY rats. Thus,ized SHRs was associated with increases in TGF-b RII
expression. TGF-b RI expression did not change in the the in vivo regulation of TGF-b receptor expression in
the glomerulus also differs between these two strains.glomeruli of the uninephrectomized SHRs with systemic
and glomerular capillary hypertension. TGF-b RI ex- Interestingly, the diabetic WKY rat develops proteinuria
and structural changes in the glomerulus, like the dia-pression did change in SHRs with diabetes mellitus.
Thus, hemodynamic factors alone are important deter- betic SHRs, so that increased TGF-b receptor expression
in the glomerulus cannot be an absolute requirementminants of glomerular TGF-b RII expression, but meta-
bolic factors are more important determinants of glomer- for development of diabetic glomerular injury [58–60].
However, the diabetic SHR does develop acceleratedular TGF-b RI expression in the SHRs.
Increases in TGF-b1 receptor expression have been albuminuria and glomerular basement thickening com-
pared to the diabetic WKY rat, and changes in TGF-breported in the glomeruli of rats with experimental mem-
branous nephropathy [51], in the renal cortex of rats receptor expression in the SHR may contribute, at least
in part, to this difference in natural history [58–60].with adriamycin-induced interstitial fibrosis [52]. In ac-
cord with our observations in glomeruli, Sharma et al In summary, we conclude that experimental type I
diabetes mellitus in hypertensive SHR is accompaniedhave reported that streptozotocin-induced diabetes mel-
litus is associated with increases in renal cortical mRNA by early increases in both TGF-b RII and TGF-b RI
expression in the glomerulus. The effect on TGF-b RIlevels for TGF-b RII in mice [30], and TGF-b RII and
RI increase in LLC-PK1 epithelial cells grown in high- expression is not mimicked by isolated glomerular capil-
lary hypertension. These studies support the hypothesisglucose concentrations in vitro [53]. The biological sig-
nificance of changes in TGF-b receptor expression in that both hemodynamic and metabolic factors can influ-
ence glomerular TGF-b receptor expression in the SHR.the kidney remains undefined, although experimental
studies have also shown that increases in TGF-b RI and Increased TGF-b receptor expression may contribute
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